Press Release: Thompson Leads Bipartisan Effort to Introduce American Manufacturing Revitalization Exchange Program Act

U.S. Representatives introduced the bipartisan American Manufacturing Revitalization Exchange Program Act to enhance training for manufacturing workers.

Quiver AI Summary

Bipartisan Legislation Introduced: This week, U.S. Representatives Glenn “GT” Thompson and several colleagues unveiled the American Manufacturing Revitalization Exchange Program Act, aimed at training future technicians, machinists, engineers, and production specialists for the U.S. manufacturing workforce.

Legislative Goals: Rep. Thompson emphasized the importance of American manufacturing for economic growth and competitiveness. The plan includes sending eligible manufacturing workers abroad for training, addressing a projected shortage of 3.8 million workers by 2033.

Support and Impact: The bill garners support from various industry groups and aims to strengthen the domestic manufacturing sector through enhanced skill development and workforce reshoring efforts, ensuring that American workers are prepared for modern manufacturing challenges.

Disclaimer: This is an AI-generated summary of a press release. The model used to summarize this release may make mistakes. See the full release here.

Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.

🏛️ Receive Alerts on Congress

Sign Up

Glenn Thompson Fundraising

Glenn Thompson recently disclosed $38.0K of fundraising in a Pre-Primary FEC disclosure filed on May 7th, 2026. This was the 395th most from all Pre-Primary reports we have seen this year. 34.2% came from individual donors.

Thompson disclosed $118.5K of spending. This was the 320th most from all Pre-Primary reports we have seen from politicians so far this year.

Thompson disclosed $732.2K of cash on hand at the end of the filing period. This was the 183rd most from all Pre-Primary reports we have seen this year.

You can see the disclosure here, or track Glenn Thompson’s fundraising on Quiver Quantitative.

Glenn Thompson Net Worth

Quiver Quantitative estimates that Glenn Thompson is worth $320.0K, as of June 5th, 2026. This is the 428th highest net worth in Congress, per our live estimates.

Thompson has approximately $0 invested in publicly traded assets which Quiver is able to track live.

You can track Glenn Thompson’s net worth on Quiver Quantitative’s politician page for Thompson.

Glenn Thompson Bill Proposals

Here are some bills which have recently been proposed by Glenn Thompson:

• H.R.9164: To amend the Richard B. Russell National School Lunch Act to require the Secretary of Agriculture to make grants to eligible entities to acquire and install milk storage-related equipment for use in elementary schools and secondary schools, and for other purposes.
• H.R.9080: To establish a contracting preference for public buildings that use innovative wood products in the construction of those buildings, and for other purposes.
• H.R.8714: Skill Savings Account Act of 2026
• H.R.7989: ACE Act
• H.R.7891: Student Aid Fraud Oversight and Accountability Act of 2026
• H.R.7885: Cybersecurity Skills Integration Act

You can track bills proposed by Glenn Thompson on Quiver Quantitative’s politician page for Thompson.

2026 Pennsylvania’s 15th Congressional District Election

There has been approximately $2,649,495 of spending in Pennsylvania’s 15th congressional district elections over the last two years, per our estimates.

The rating for this race is currently “Solid R”.

You can track this election on our matchup page for the 2026 Pennsylvania’s 15th congressional district election.

Source link

U.S. Should Substantially Boost Support for Manufacturing USA Program, Issue National Industrial Manufacturing Strategy, Says New Report

To better compete globally, the United States should develop a comprehensive industrial strategy to align resources for manufacturing and maximize the national security and economic impacts of the Manufacturing USA program, a proven model that connects the key actors — small and large industry, engineering and science expertise, state and local government, and economic development stakeholders — needed to advance progress in manufacturing technology, says a new report by the National Academies of Sciences, Engineering, and Medicine. Nearly all leading competitor nations have detailed national manufacturing strategies that are aligned with their national economic strategies and view manufacturing as crucial to their growth and national security, the report says.

Strengthening the Manufacturing USA program — a public-private partnership coordinated through the National Institute of Standards and Technology comprising 17 institutes that specialize in different types of advanced manufacturing — is essential for bolstering U.S. competitiveness in the next decade, the report says. The network of institutes is a vital national asset that plays a central role in aligning innovation efforts across government, industry, and academia, connecting American businesses of all sizes with state-of-the-art technology and translating the latest breakthroughs into industrial practice.

However, the report says, the nation is missing a coordinated framework to align industry and government efforts, which has led to under-resourcing federal manufacturing programs, including Manufacturing USA, and a lack of investments to scale up production in proven areas.

As a result, U.S. manufacturing productivity — once a hallmark of the economy — has declined markedly in the past 15 years, the report says. China has been the world leader of manufacturing output since 2011, and currently holds around 35 percent of gross world manufacturing, compared to 12 percent in the U.S. The U.S. trade deficit in goods has also risen sharply, reaching a record $1.2 trillion in 2025, which includes a major deficit in advanced technologies such as aircraft, semiconductors, and robots.

“Even though the U.S. develops many manufacturing technologies, the nation continues to outsource most of its manufacturing and lags far behind other nations in production capacity,” said Theresa Kotanchek, chief executive officer of Evolved Analytics LLC and chair of the committee that wrote the report. “This presents risks to our supply chains, our economy, and our national security if we can’t access critical technologies when we need them most. Our report outlines actions to strengthen the Manufacturing USA program and U.S. advanced manufacturing so that we can grow the businesses and produce the technologies we need at home.”

The report calls on the National Economic Council, Office of Science and Technology Policy, the departments of Commerce, Defense, and Energy, and other agencies to develop within the next two years an industrial strategy — in concert with the National Security Strategy — that integrates technology development, scale-up financing, and leadership in standards, trade, and workforce development so that resources are aligned for a more robust U.S. advanced manufacturing posture.

Informed by tools available in leading advanced manufacturing countries, Congress and federal agencies should set policy to create new federal manufacturing and financing mechanisms that include long-term investment vehicles such as patient-capital funds, a sovereign wealth fund with a strategic focus on manufacturing, and intellectual-property backed lending financing. In addition, Congress should create a globally competitive research and development tax credit for manufacturing processes and technologies, as well as explore expanding other tax reforms that support manufacturing.

Congress should provide sustained, dedicated funding above current appropriations by 2030 to establish business development offices at each Manufacturing USA institute, the report says. These offices would support commercialization, scale-up, and regional ecosystem integration, particularly for entrepreneurs and small- and medium-sized manufacturers (SSMs) working in coordination with regional economic development organizations and federal manufacturing programs.

Technology transfer is central to the Manufacturing USA mission. Institutes need to support two small firm extremes, both of which often lack the capital and resources to scale up — at one end, small, innovative entrepreneurs with good ideas to develop nascent technologies and at the other, SSMs that need to implement proven technologies. Additionally, large, multinational corporations that are institute members want to accelerate technology transfer to reduce their risks in scaling up investments. The report recommends establishing dedicated in-house technology transfer teams to help bridge the innovation “valley of death” between early-stage research and full-scale production.

Supporting robust pathways to careers in advanced manufacturing is necessary to cultivate a skilled workforce that can operate, maintain, and improve complex emerging manufacturing technologies in areas such as robotics, data analysis, digital production, and new materials. Yet, attracting and retaining talent remains a challenge, the report says.

“Collaboration across institutions and work sectors, to align student outcomes with industry needs, is necessary for the U.S. to become a leader in advanced manufacturing,” said National Academy of Engineering President Tsu-Jae Liu. “This report highlights the importance of workforce development for achieving and maintaining a competitive edge in advanced manufacturing, for economic prosperity and national security. 

Manufacturing USA institutes should adopt a broad range of programs to address workforce education needs that are built around a unified advanced manufacturing curriculum, the report says. In collaboration with regional stakeholders, this should include broad support for manufacturing apprenticeships and the development of comprehensive online advanced manufacturing courses.

The report also calls for a new interagency council to enable cross-agency and cross-institute collaboration, reduce administrative barriers, develop a digital manufacturing strategy, and establish an integrated strategy for the manufacturing institutes. Cross-agency collaboration is important between institute sponsoring agencies as well as between the institutes and other federal programs, including the national laboratories and the Manufacturing Extension Partnership program, to ensure advanced manufacturing technologies developed by the institutes are disseminated widely. Federal funding on par with comparable effective programs abroad is critical for supporting these activities.

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, engineering, and medicine. They operate under an 1863 congressional charter to the National Academy of Sciences, signed by President Lincoln.

For more information, visit https://www.nationalacademies.org/.

Source link

SBA’s Empower to Grow program boosts training support for U.S. manufacturing

LINCOLN, Neb — Small manufacturers and the training organizations that support them have a new opportunity for funding and technical assistance through the U.S. Small Business Administration’s Empower to Grow (E2G) Program, including its Manufacturing in America E2G Grant Initiative.

The initiative aims to strengthen American manufacturing by directing resources to regional and national training providers to help businesses build capacity and overcome challenges. The program is designed to support hands-on training in areas such as advanced robotics, streamlining daily operations and navigating compliance requirements.

The initiative is intended to serve a wide range of industries, including aerospace, food processing, metal fabrication and construction equipment.

Organizations seeking to participate must submit proposals electronically through www.grants.gov by June 15 at 11:59 p.m. EDT.

The SBA is also offering free informational webinars on May 27 and June 3. Questions and requests for more information can be directed to e2g@sba.gov.

The SBA says the effort is part of a broader commitment to small manufacturers, including access to resources such as loan guarantees and simplified programs aimed at helping businesses grow and keep jobs local.

Source link

Kumar Named to ACMA Emerging Leaders Program for 2026

BYLINE: Tina M. Johnson

Newswise — Vipin Kumar, a composites manufacturing researcher at the Department of Energy’s Oak Ridge National Laboratory, has been named one of 21 rising professionals nationwide for the 2026 Emerging Leaders Program of the American Composites Manufacturers Association (ACMA).

The competitive, year-long program develops future leaders in the composites industry through professional development, industry engagement and advocacy training, preparing participants to help shape the future of advanced manufacturing in the United States.

“Vipin translates cutting-edge research into solutions that industry can use. His selection for the ACMA Emerging Leaders Program reflects both his exceptional technical expertise and his growing influence as a leader in advanced manufacturing,” said Yarom Polsky, director of ORNL’s Manufacturing Science Division. “This recognition underscores ORNL’s commitment to developing leaders who will advance U.S. manufacturing competitiveness.”

Kumar’s work at DOE’s Manufacturing Demonstration Facility (MDF) at ORNL focuses on developing innovative composite manufacturing techniques using large-scale polymer additive manufacturing, along with traditional and advanced manufacturing processes. He also investigates how carbon fiber-reinforced plastic composites respond to direct lightning strikes and is designing novel materials to mitigate damage, improving safety and resilience for applications such as aerospace.

Kumar has published more than 120 peer-reviewed journal articles and conference proceedings and holds three granted patents, with 12 additional patents pending. He received a 2023 R&D 100 Award and the 2023 CAMX Combined Strength Award for his contributions to ORNL’s additive manufacturing-compression molding process, a significant advancement in high-throughput thermoplastic composite production. He also received the 2022 Outstanding Young Manufacturing Engineer Award from the Society of Manufacturing Engineers and the 2021 Young Professionals Emerging Leadership Award from the Society for the Advancement of Material and Process Engineering.

The MDF is supported by DOE’s Advanced Materials and Manufacturing Technologies Office and acts as a nationwide consortium of collaborators focused on innovating, inspiring and catalyzing the transformation of U.S. manufacturing.

UT-Battelle manages ORNL for the DOE’s Office of Science, the single largest supporter of basic research in the physical sciences in the United States. The Office of Science is working to address some of the most pressing challenges of our time. For more information, please visit energy.gov/science. — Tina M. Johnson

Source link

FDA Announces New Domestic-Manufacturing-Focused Pilot Program

The current administration continues efforts to boost domestic manufacturing.

One of President Trump’s stated goals across all industry has been a desire to reduce the United State’s dependence on imported goods. While he has targeted a wide swath of industries, he has specifically targeted the pharmaceutical industry.

This is most likely due to this particular issue playing a key role in another of the President’s initiatives, reducing the cost of pharmaceuticals in the United States.

On February 1, FDA announced a new pilot program designed to promote the construction of domestic manufacturing sites, along with increasing regulatory predictability and and streamlining manufacturing facility assessments.1

FDA PreCheck will begin in 2026 and include a group of domestic facilities that the agency says are aligned with national priorities. The criteria used to decide this will be:

• Products to be manufactured
• Phase of facility development
• Timeline to producing products to US market
• Innovation in facility development

Also, any facility developing critical medications for the US market will be considered for the initial group.

In a statement FDA Commissioner Marty Makary, MD, MPH, said, “After 35 years of globalists taking pharmaceutical manufacturing overseas, the FDA is taking bold steps to bring it back. The PreCheck program is one of several powerful incentives we are providing to make the U.S. pharmaceutical manufacturing sector more resilient and competitive.”

This is just the latest effort by FDA to promote domestic manufacturing and reduce dependence on imports.

In late January, the agency announced the results of the ImportShield Program, which aims to bring consistent oversight to the import review process across the entire country.2 In order to achieve this, the existing five regional teams were restructured into just one centralized team.

According to FDA, this resulted in:

• An increase to processing speed by 66%
• An increase to monthly volume capacity by 33%
• A reduction in staff hours by 20%

In a press release, Makary said, “Whether it’s detecting counterfeit medications or identifying contaminated food products, the FDA ImportShield Program and other modernization efforts add a powerful new layer of protection for American families.”

Meanwhile, major pharmaceutical companies have been announcing major manufacturing projects within the United States.

The latest example of this is Eli Lilly, who just announced plans to invest $3.5 billion in a manufacturing facility in Lehigh Valley, Pennsylvania.3 The site will focus on injectal medicine and device manufacturing. The site should be operational by 2031.

In a press release, Lilly chair and CEO David A. Ricks said, “”Our mission starts with patients and delivering the medicines they need. To meet increasing demand, we’re expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next‑generation weight-loss medicines. We’re creating high‑quality jobs and collaborating across the region—with suppliers, educators, and workforce‑development partners—to make critical medicines in the U.S. That’s our commitment—to patients, to our new Pennsylvania home and to our country.”

In the same press release, Pennsylvania Governor Josh Shapiro said, “”When we announced our Economic Development Strategy here in the Lehigh Valley two years ago, we set out to win historic, life-changing deals like the one we’re announcing with Lilly today. Before I took office, Pennsylvania wasn’t even in the conversation for major investments like this, but thanks to our work to cut red tape, invest in site development, and expand our workforce, our Commonwealth is now competing—and winning—on a national scale. Lilly’s commitment to the Lehigh Valley and to Pennsylvania will bring billions of dollars of investment and hundreds of good-paying jobs, solidifying our position as a leader in the growing life sciences industry.”

Sources

1. FDA Launches PreCheck Pilot Program to Strengthen Domestic Pharmaceutical Manufacturing. FDA. February 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-precheck-pilot-program-strengthen-domestic-pharmaceutical-manufacturing
2. FDA ImportShield Program Delivers Impressive Results in Strengthening FDA Oversight at U.S. Ports of Entry. FDA. January 21, 2026. https://www.fda.gov/news-events/press-announcements/fda-importshield-program-delivers-impressive-results-strengthening-fda-oversight-us-ports-entry
3. Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility. Eli Lilly. January 30, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-selects-pennsylvania-home-its-newest-injectable-medicine

Source link

US FDA launches program to boost domestic drug manufacturing

By Ahmed Aboulenein

WASHINGTON, Feb 1 (Reuters) – The U.S. Food and Drug Administration on Sunday began accepting requests to participate in its PreCheck pilot program, designed to ​boost domestic drug supply by speeding up construction and review of drug manufacturing ‌plants in the country.

The FDA said it would select an initial group of new pharmaceutical manufacturing facilities this year ‌based on “alignment with national priorities” in several areas including the product itself, how quickly it can be developed for the U.S. market, and innovations in facility development.

“Additional priority considerations will be given to facilities producing critical medications for the U.S. market,” the agency said in a statement.

The ⁠FDA PreCheck program, first announced ‌in August, aims to streamline review of domestic pharmaceutical plants and eliminate unnecessary regulatory requirements, in line with President Donald Trump’s executive order in ‍May to shift manufacturing of drugs to the United States.

The program introduces a two-phase approach to facilitate new U.S. drug manufacturing facilities.

The initial phase would provide for more frequent communication with the FDA, including ​for facility design, construction and pre-production.

The second phase would facilitate pre-application meetings and early ‌feedback to help streamline the development of manufacturing and quality control processes, the agency said.

The FDA had separately announced another program in June to incentivize drug developers that align with national priorities, including increased domestic manufacturing, with shortened times for reviewing marketing applications.

The FDA Commissioner’s National Priority Voucher Program promised decisions in one or two months on a limited number of ⁠drugs deemed critical to public health or national security, ​cutting four to six months off the fastest priority ​approval process.

Reuters, citing internal documents, reported exclusively last month that the agency had delayed reviews of two drugs chosen for the new fast-track program after ‍agency scientists flagged safety ⁠and efficacy concerns, including the death of a patient while taking one of the medicines.

Two other drugs tapped for the speedy review program have also been pushed by ⁠weeks or longer beyond the original target date. The four drugs are among at least seven in the ‌program that have started their approval process, according to documents.

(Reporting by Ahmed ‌Aboulenein; Editing by Sergio Non and Chizu Nomiyama )

Source link